162 related articles for article (PubMed ID: 16146840)
1. FLT3 antibody-based therapeutics for leukemia therapy.
Li Y; Zhu Z
Int J Hematol; 2005 Aug; 82(2):108-14. PubMed ID: 16146840
[TBL] [Abstract][Full Text] [Related]
2. Targeting FMS-related tyrosine kinase receptor 3 with the human immunoglobulin G1 monoclonal antibody IMC-EB10.
Youssoufian H; Rowinsky EK; Tonra J; Li Y
Cancer; 2010 Feb; 116(4 Suppl):1013-7. PubMed ID: 20127944
[TBL] [Abstract][Full Text] [Related]
3. IMC-EB10, an anti-FLT3 monoclonal antibody, prolongs survival and reduces nonobese diabetic/severe combined immunodeficient engraftment of some acute lymphoblastic leukemia cell lines and primary leukemic samples.
Piloto O; Nguyen B; Huso D; Kim KT; Li Y; Witte L; Hicklin DJ; Brown P; Small D
Cancer Res; 2006 May; 66(9):4843-51. PubMed ID: 16651440
[TBL] [Abstract][Full Text] [Related]
4. Anti-human FLT3 monoclonal antibody that inhibits proliferation of monocytic leukemia cell line SHI-1.
Ju S; Xue Z; Ju S; Ge Y; Xie W; Zhu H; Pan J; Zhang X
Hybridoma (Larchmt); 2011 Feb; 30(1):61-7. PubMed ID: 21466287
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory anti-FLT3 antibodies are capable of mediating antibody-dependent cell-mediated cytotoxicity and reducing engraftment of acute myelogenous leukemia blasts in nonobese diabetic/severe combined immunodeficient mice.
Piloto O; Levis M; Huso D; Li Y; Li H; Wang MN; Bassi R; Balderes P; Ludwig DL; Witte L; Zhu Z; Hicklin DJ; Small D
Cancer Res; 2005 Feb; 65(4):1514-22. PubMed ID: 15735040
[TBL] [Abstract][Full Text] [Related]
6. Generation, selection and preclinical characterization of an Fc-optimized FLT3 antibody for the treatment of myeloid leukemia.
Hofmann M; Große-Hovest L; Nübling T; Pyż E; Bamberg ML; Aulwurm S; Bühring HJ; Schwartz K; Haen SP; Schilbach K; Rammensee HG; Salih HR; Jung G
Leukemia; 2012 Jun; 26(6):1228-37. PubMed ID: 22289926
[TBL] [Abstract][Full Text] [Related]
7. [Possibility of targeting FLT3 kinase for the treatment of leukemia].
Kiyoi H
Rinsho Ketsueki; 2005 Mar; 46(3):187-97. PubMed ID: 16447713
[No Abstract] [Full Text] [Related]
8. Isolation of human mAbs that directly modulate FMS-related tyrosine kinase 3 signaling.
Yamamoto Y; Tsuzuki S; Akahori Y; Ukai Y; Sumitomo M; Murayama Y; Yamamoto K; Inaguma Y; Tokuda M; Abe A; Akatsuka Y; Emi N; Kurosawa Y
Cancer Sci; 2012 Feb; 103(2):350-9. PubMed ID: 22049994
[TBL] [Abstract][Full Text] [Related]
9. Cell-based selection of internalizing fully human antagonistic antibodies directed against FLT3 for suppression of leukemia cell growth.
Williams B; Atkins A; Zhang H; Lu D; Jimenez X; Li H; Wang MN; Ludwig D; Balderes P; Witte L; Li Y; Zhu Z
Leukemia; 2005 Aug; 19(8):1432-8. PubMed ID: 15931264
[TBL] [Abstract][Full Text] [Related]
10. SKLB-677, an FLT3 and Wnt/β-catenin signaling inhibitor, displays potent activity in models of FLT3-driven AML.
Ma S; Yang LL; Niu T; Cheng C; Zhong L; Zheng MW; Xiong Y; Li LL; Xiang R; Chen LJ; Zhou Q; Wei YQ; Yang SY
Sci Rep; 2015 Oct; 5():15646. PubMed ID: 26497577
[TBL] [Abstract][Full Text] [Related]
11. A novel FLT3 inhibitor FI-700 selectively suppresses the growth of leukemia cells with FLT3 mutations.
Kiyoi H; Shiotsu Y; Ozeki K; Yamaji S; Kosugi H; Umehara H; Shimizu M; Arai H; Ishii K; Akinaga S; Naoe T
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4575-82. PubMed ID: 17671144
[TBL] [Abstract][Full Text] [Related]
12. IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction.
Phillips KE; Herring B; Wilson LA; Rickford MS; Zhang M; Goldman CK; Tso JY; Waldmann TA
Cancer Res; 2000 Dec; 60(24):6977-84. PubMed ID: 11156399
[TBL] [Abstract][Full Text] [Related]
13. Integration of monoclonal antibodies and immunoconjugates into the treatment of acute myeloid leukemia.
Amadori S; Stasi R
Curr Opin Hematol; 2008 Mar; 15(2):95-100. PubMed ID: 18300754
[TBL] [Abstract][Full Text] [Related]
14. FLT3/internal tandem duplication subclones in acute myeloid leukemia differ in their engraftment potential in NOD/SCID mice.
Cheung AM; Chow HC; Kwong YL; Liang R; Leung AY
Leuk Res; 2010 Jan; 34(1):119-22. PubMed ID: 19683812
[TBL] [Abstract][Full Text] [Related]
15. [An overview of antibody-based cancer therapy].
Miao QF; Shao RG; Zhen YS
Yao Xue Xue Bao; 2012 Oct; 47(10):1261-8. PubMed ID: 23289136
[TBL] [Abstract][Full Text] [Related]
16. Activating Fc receptors are required for antitumor efficacy of the antibodies directed toward CD25 in a murine model of adult t-cell leukemia.
Zhang M; Zhang Z; Garmestani K; Goldman CK; Ravetch JV; Brechbiel MW; Carrasquillo JA; Waldmann TA
Cancer Res; 2004 Aug; 64(16):5825-9. PubMed ID: 15313926
[TBL] [Abstract][Full Text] [Related]
17. What are the latest advancements in acute myeloid leukemia therapy?
Goodman A; Ball ED
Future Oncol; 2017 Apr; 13(10):867-871. PubMed ID: 28266249
[No Abstract] [Full Text] [Related]
18. [FLT3 inhibitors for acute myeloid leukemia].
Kiyoi H
Nihon Rinsho; 2014 Jun; 72(6):1035-41. PubMed ID: 25016800
[TBL] [Abstract][Full Text] [Related]
19. Anti-CD7 antibody and immunotoxin treatment of human CD7(+)T-cell leukaemia is significantly less effective in NOD/LtSz-scid mice than in CB.17 scid mice.
Flavell DJ; Warnes SL; Noss AL; Flavell SU
Br J Cancer; 2000 Dec; 83(12):1755-61. PubMed ID: 11104577
[TBL] [Abstract][Full Text] [Related]
20. Characterization of a bispecific FLT3 X CD3 antibody in an improved, recombinant format for the treatment of leukemia.
Durben M; Schmiedel D; Hofmann M; Vogt F; Nübling T; Pyz E; Bühring HJ; Rammensee HG; Salih HR; Große-Hovest L; Jung G
Mol Ther; 2015 Apr; 23(4):648-55. PubMed ID: 25578618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
